KRAS and familial pancreatic carcinoma: Knocking down PIP5K1A expression specifically reduced the viability of KRAS transformed cells versus NRAS or HRAS mutated cancer cells and had an additive effect with MEK inhibitors in KRAS mutant pancreatic cancer cell models.